Literature DB >> 2210377

Induction by HMBA and DMSO of genes introduced into mouse erythroleukemia and other cell lines by transient transfection.

P L Campbell1, A E Kulozik, J P Woodham, R W Jones.   

Abstract

We have found rapid induction of various genes, including human globin genes, in response to hexamethylene bisacetamide (HMBA) and dimethyl sulfoxide (DMSO) in transiently transfected cells. In mouse erythroleukemia cells (MELCs), this effect is detected within 1 hr of exposure of the cells to inducer before the endogenous mouse globin genes are induced. It does not require protein synthesis and is reversed if the inducer is removed. This and other evidence suggest that the mechanism involves a change in activity of a factor intimately involved with transcription, probably as a result of post-translational modification. As such, it may represent an early triggering event in terminal differentiation, and its relevance to the expression of human globin genes in stable transfectants and to induction of the mouse globin genes is discussed. Other cell lines (K562 and NSO) also show this response, which may therefore involve a ubiquitous mechanism. We also found that HMBA depresses the expression of endogenous globin genes in K562, the opposite of this differentiation inducer's effect on MELC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210377     DOI: 10.1101/gad.4.7.1252

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  10 in total

1.  A second ferritin L subunit is encoded by an intronless gene in the mouse.

Authors:  F Renaudie; A K Yachou; B Grandchamp; R Jones; C Beaumont
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

2.  Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis.

Authors:  C M Preston; M J Nicholl
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation.

Authors:  Vladimir Klichko; Nancy Archin; Rupinderjeet Kaur; Ginger Lehrman; David Margolis
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Determination of mRNA fate by different RNA polymerase II promoters.

Authors:  J Enssle; W Kugler; M W Hentze; A E Kulozik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 5.  Molecular biology of herpes simplex virus type 1 latency in the nervous system.

Authors:  I Steiner; P G Kennedy
Journal:  Mol Neurobiol       Date:  1993       Impact factor: 5.590

6.  The erythroid Krüppel-like factor transactivation domain is a critical component for cell-specific inducibility of a beta-globin promoter.

Authors:  J J Bieker; C M Southwood
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

7.  Nuclear degradation of nonsense mutated beta-globin mRNA: a post-transcriptional mechanism to protect heterozygotes from severe clinical manifestations of beta-thalassemia?

Authors:  W Kugler; J Enssle; M W Hentze; A E Kulozik
Journal:  Nucleic Acids Res       Date:  1995-02-11       Impact factor: 16.971

8.  The LCR-like alpha-globin positive regulatory element functions as an enhancer in transiently transfected cells during erythroid differentiation.

Authors:  M D Pondel; M George; N J Proudfoot
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

9.  Ca2+ signalling in K562 human erythroleukaemia cells: effect of dimethyl sulphoxide and role of G-proteins in thrombin- and thromboxane A2-activated pathways.

Authors:  C P Thomas; M J Dunn; R Mattera
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

10.  Initiation of DNA replication at the human beta-globin 3' enhancer.

Authors:  Alla Buzina; Mirit I Aladjem; John L Kolman; Geoffrey M Wahl; James Ellis
Journal:  Nucleic Acids Res       Date:  2005-08-05       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.